Showing results (151-160 of 216) with videos related to
Sort By:
Pageof 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLCDongchen Sun, Jiaqing Liu, Huaqiang Zhou, et al.Journal of Thoracic Disease|January 17, 2023
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trialYuxiang Ma, Hui Pan, Yu Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2014
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)Hongyun Zhao, Yun Fan, Shenglin Ma, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 26, 2020
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]Caicun Zhou, Jie Wang, Hong Bu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical <i>EGFR</i> Mutations: A Phase Ib StudyHuaqiang Zhou, Hongyun Zhao, Xue Hou, et al.Chinese Journal of Cancer|November 27, 2016
Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatmentWenhua Liang, Guanzhu Shen, Yaxiong Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with Locally Advanced or Metastatic Epithelial Tumor: Results from first-in-human phase I/Ib studyJinhui Xue, Yuxiang Ma, Yuanyuan Zhao, et al.Clinical and Translational Medicine|June 9, 2020
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancerZhonghan Zhang, Yang Zhang, Fan Luo, et al.Journal for Immunotherapy of Cancer|June 1, 2023
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumorsYuxiang Ma, Jinhui Xue, Yuanyuan Zhao, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 31, 2020
The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in ChinaJuan Yu, Zhen Zhang, Huaqiang Zhou, et al.Pageof 22